No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study

Abstract

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis

“…No observational studies on exercise or sedentary behavior were found. A retrospective study design was used for all but three included studies [ 44 , 45 , 46 ]. Patients with FIGO stage III-IV were included in 39 studies, 30 studies included patients with all stages, 2 studies included FIGO stage I-II, and stage was not specified in 2 other studies.…”

Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications

“…A measurement error of 2% was used based on previously reported accuracy of CT for muscle and fat tissue analysis [12,28]. Loss/gain of skeletal muscle mass or density was defined as >2% decrease/increase per 100 days, in line with Rutten et al [12] and Ubachs et al [14].…”

“…Future studies on prehabilitation programs to lower the risk for postoperative complications could further investigate which patients are prone for muscle density loss, how to prevent decline in skeletal muscle density and whether this is effective in preventing postoperative complications. Furthermore, we used the same method to define loss of skeletal muscle mass and density as the largest of the three currently available studies [12] [e] [14] on CTmeasured changes in body composition among patients treated with NACT for ovarian cancer, facilitating the ability to compare results. Also, all CT measurements were executed by a board certified radiologist with extensive experience [26].…”

“…In line with low preoperative skeletal muscle mass and density, loss of skeletal muscle mass during NACT could be a useful marker in predicting adverse treatment outcomes in patients with ovarian cancer [12,13], but current evidence is not unanimous yet [14]. Loss of skeletal muscle mass or density could be target points for prehabilitation, to prevent or minimize loss and decreasing the risk for worse postoperative outcomes.…”

“…If a variable has 5 missing values, the number presented behind a variable represents the number of patients included in this analysis. Loss of skeletal muscle density is defined as >2% decrease per 100 days in skeletal muscle density during neoadjuvant chemotherapy[12,14].…”